Chengyu Liu obtained his Ph.D. from University of California-Irvine studying developmental biology. After a postdoctoral training at Roche Institute of Molecular Biology, he established and managed the Transgenic Core at the Columbia University Comprehensive Cancer Center. Since 1999, he has been running the Transgenic Core at the National Heart, Lung, and Blood Institute of NIH. He is familiar with essentially all methods related to the creation of transgenic and knockout/knockin mouse models, including the classical ES-cell based homologous recombination as well as the more recent genome engineering methods, especially the CRISPR/Cas9 technology. His core has generated hundreds of genetically engineered mouse models to support NIH investigators in their research and collaborated with some laboratories in developing new technologies.
Kenton Abel, Ph.D., is cofounder, President, & Chairman of Object Pharma, Inc. Dr. Abel was a cofounder and employee #1 at Bonti, Inc., a startup company developing a short duration cousin to Botox® for treating acute muscle injuries. Allergan purchased Bonti in October 2018 for $195 million cash, plus additional milestone payments. Dr. Abel has over 18 years of intellectual property experience, primarily focused on IP strategy and patent prosecution. Other experience includes patent, copyright, and trade secret litigation and IP counseling. Dr. Abel received a Bachelor Degree of Science in Chemistry from Pacific Union College, a Ph.D. in Biochemistry from the University of California, Riverside, and a law degree from the University of California, Berkeley.
Xiao Wen “Vivien” Mao
Phone: 909-558-8373 Ext. 88373
For Poster Presentation Information:
Erik J. Behringer
For Symposium Organization: